[Skip to Content]
[Skip to Content Landing]
Correspondence
Aug 2012

Eczematous Drug Eruption After Ustekinumab Treatment

Arch Dermatol. 2012;148(8):959-960. doi:10.1001/archdermatol.2012.586

Ustekinumab is a human monoclonal antibody that blocks interleukin (IL)-12 and IL-23, 2 cytokines that play an important role in the pathogenesis of psoriasis.1,2 It was approved in 2009 for the treatment of adult moderate to severe chronic plaque psoriasis. We report herein the first case to our knowledge of a patient with an eczematous eruption that appeared after the administration of ustekinumab.

×